Skip to main content
SpringerLink
Log in

Ropinirole: a promising new antiparkinsonian drug

  • New drugs and disease management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Lambert D, Waters CH. Comparative tolerability of the newer generation antiparkinsonian agents. Drugs Aging 2000 Jan; 16(1): 55–65

    Article  CAS  PubMed  Google Scholar 

  2. Matheson AJ, Spencer CM. Ropinirole. A review of its use in the management of Parkinson’s disease. Drugs 2000 Jul; 60(1): 115–37

    Article  CAS  PubMed  Google Scholar 

  3. Rascol A, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med 2000; 342(20): 1484–91

    Article  CAS  PubMed  Google Scholar 

  4. Korczyn AD, Brunt ER, Larsen JP, et al. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson’s disease [erratum published in Neurology 1999; 53: 1162]. Neurology 1999; 53(2): 364–70

    Article  CAS  PubMed  Google Scholar 

  5. Ropinirole 043 Study Group. A double-blind comparative study of ropinirole vs bromocriptine in the treatment of Parkinsonian patients not optimally controlled on l-dopa. Mov Disord 1996; 11 Suppl. 1: 188

    Google Scholar 

  6. Brunt ER, Korczyn AD, Lieberman A, et al. The long-term efficacy of ropinirole as an adjunct to L-dopa [abstract]. Neurology 1999; 52 Suppl. 2: A408–409

    Google Scholar 

  7. Brooks DJ, Rakshi JS, Pavese N, et al. Relative rates of progression of early Parkinson’s diseaese patients started on either a dopamine agonist (ropinirole) or levodopa: 2-year and 5-year follow-up 18F-dopa PET findings [abstract]. Neurology 2000; 54 Suppl. 3: A113

    Google Scholar 

  8. Stocchi F, Destee A. Co-administration of ropinirole and domperidone during rapid dose escalation of the dopamine agonist. Parkinsonism and Related Disorders 1998; 4(4): 183–8

    Article  CAS  PubMed  Google Scholar 

  9. Rascol O, Lees AJ, Senard JM, et al. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson’s disease. Clin Neuropharmacol 1996 Jun; 19: 234–45

    Article  CAS  PubMed  Google Scholar 

  10. Schrag AE, Brooks DJ, Brunt E, et al. The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson’s disease. Clin Neuropharmacol 1998 May–Jun; 21: 169–75

    CAS  PubMed  Google Scholar 

  11. Hristova AH, Koller WC. Early Parkinson’s disease. What is the best approach to treatment. Drugs Aging 2000 Sep; 17(3): 165–81

    Article  CAS  PubMed  Google Scholar 

  12. British National Formulary No. 40. London: The Pharmaceutical Press, 2000 Sep: 234-40

  13. Drug Topics Red Book. Montvale (NJ): Medical Economics Company, 2000

  14. Physician’s Desk Reference. 55th ed. Montvale (NJ): Medical Economics Company 2001

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ropinirole: a promising new antiparkinsonian drug. Drugs Ther. Perspect 17, 1–5 (2001). https://doi.org/10.2165/00042310-200117060-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200117060-00001

Keywords

Search

Navigation